SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: January
GICS Industry Group : Health Care Equipment & Services
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.57

26 Oct
2021

0.000

OPEN

$0.57

0.000

HIGH

$0.58

606,489

LOW

$0.56

TARGET
$0.65 14.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . MCP . API . BKL . EXL . CLV .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 6.1 3.4 xxx
DPS (cps) xxx 1.0 2.5 xxx
EPS Growth xxx N/A - 44.4% xxx
DPS Growth xxx 0.0% 100.0% xxx
PE Ratio xxx N/A 16.9 xxx
Dividend Yield xxx N/A 4.4% xxx
Div Pay Ratio(%) xxx 16.5% 75.1% xxx

Dividend yield today if purchased 3 years ago: 1.89%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.75

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/04 - ex-div 1c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx6.1
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx3,400.4 M
Book Value Per Share xxxxxxxxxxxxxxx54.1
Net Operating Cash Flow xxxxxxxxxxxxxxx12.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.76 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx11.83 %
Return on Invested Capital xxxxxxxxxxxxxxx9.14 %
Return on Assets xxxxxxxxxxxxxxx4.84 %
Return on Equity xxxxxxxxxxxxxxx11.83 %
Return on Total Capital xxxxxxxxxxxxxxx-9.85 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-64.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

22/09/2021

1

Outperform

$0.70

22.81%

In its first half results, Sigma Healthcare has downgraded guidance because of the lingering nature of the pandemic, now expecting EBITDA growth in FY22 of 5% instead of 10%.

The company now expects FY23 EBITDA of $95-100m. As a result, Credit Suisse lowers estimates by around -5% across the forecast period.

The broker believes the bid by Wesfarmers ((WES)) for Australian Pharmaceutical ((API)) signals Sigma Healthcare is undervalued. Outperform rating maintained. Target is reduced to $0.70 from $0.73.

FORECAST
Credit Suisse forecasts a full year FY22 dividend of 2.29 cents and EPS of 3.10 cents.
Credit Suisse forecasts a full year FY23 dividend of 2.72 cents and EPS of 3.63 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SIG STOCK CHART